Quick Take
Avidity Biosciences (RNA) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is developing treatments for diseases including various dystrophies and Pompe disease.
RNA is a very early stage firm but has a significant collaboration and investment relationship with Eli Lilly & Co.
I’ll provide an update when we learn more IPO details.
Company & Technology
La Jolla, California-based Avidity was founded to develop what it calls its Antibody Oligonucleotide Conjugate [AOC] platform for combining the tissue selectivity of